SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

Patient Assistance

Provide your PNH patients ongoing personalized treatment support and medication access with SOLIRIS OneSource. Call 1.888.SOLIRIS (1.888.765.4747) to speak to an Alexion Case Manager.

The Alexion Commitment to Access

Alexion's goal is to ensure that every patient who is a medical candidate for SOLIRIS® (eculizumab) will have access to SOLIRIS. The Alexion Case Manager works with patients who do not have insurance, do not have adequate insurance, and/or do not have access to any other means for obtaining SOLIRIS to determine and facilitate a plan to obtain access.

  • The National Organization for Rare Diseases (NORD) has established a PNH Foundation to assist underinsured patients in meeting out-of-pocket or ancillary expenses (e.g., premium or co-payments) related to treatment of PNH. For further information, visit NORD at http://www.rarediseases.org/programs/medication or call 1-800-999-6673
     
  • The Alexion COMPLEMENT Foundation (a private, charitable organization) was established to facilitate access to SOLIRIS for patients who reside in the U.S. and do not have access to insurance or any other means of obtaining SOLIRIS. Following your patient's enrollment into SOLIRIS OneSource™, and upon request, an Alexion Case Managers will make referrals to the Foundation for patients who may qualify.

Next: Office Coding for SOLIRIS

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.